AxioMed will also be conducting a post-market study of the device’s treatment of cervical degenerative disc disease, and the results are expected to be used in a future Investigational Device Exemption to the FDA.
More Articles on Devices:
Dr. Jason Highsmith Performed First Precision Spectra Spinal Cord Stimulator Implant
Legislation to Repeal 2.3% Medical Device Tax Introduced in Senate
Smith & Nephew Profits Up 1% in 4Q, Revenue Dips 3%
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
